Samrotamab, also known as tiragolimod, represents a notable advance in cancer study. This novel targeted protein is currently in clinical evaluation and demonstrates impressive ability for targeting multiple tumors, https://bookmarklinking.com/story10933742/samrotamab-a-promising-monoclonal-antibody-in-progress